Early results of two Phase III studies with Sanofi-Synthelabo’s Acomplia (rimonabant), the first in a new class of therapeutics called Selective CB1 Blockers, indicate that overweight/obese patients with untreated dyslipidemia (high triglycerides and/or high total cholesterol/HDL cholesterol ratio) lost weight …